Healthcare provider profile · identity verified

Jorge A Alfonso, MD

Allopathic & Osteopathic Physicians|Internal Medicine · SOUTH YARMOUTH, MA · NPI 1013983402

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jorge A Alfonso, MD received $77.50 in general payments during 2025 across 4 reported records.

Novo Nordisk Inc accounted for 31.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$77.50

4 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$24.48	31.6%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$18.35	23.7%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$18.20	23.5%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$16.47	21.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$77.50	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$24.48	1	2025
Source payment records 2025-08-20 · Novo Nordisk Inc · $24.48 · Open Payments source
AREXVY Normalized: arexvy	Biological	GlaxoSmithKline, LLC.	$18.35	1	2025
Source payment records 2025-03-31 · GlaxoSmithKline, LLC. · $18.35 · Open Payments source
SHINGRIX Normalized: shingrix	Biological	GlaxoSmithKline, LLC.	$18.35	1	2025
Source payment records 2025-03-31 · GlaxoSmithKline, LLC. · $18.35 · Open Payments source
KISUNLA Normalized: kisunla	Drug	Lilly USA, LLC	$18.20	1	2025
Source payment records 2025-06-17 · Lilly USA, LLC · $18.20 · Open Payments source
BREZTRI Normalized: breztri	Drug	AstraZeneca Pharmaceuticals LP	$16.47	1	2025
Source payment records 2025-06-09 · AstraZeneca Pharmaceuticals LP · $16.47 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	33	14
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	28	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	791	237
Losartan Potassium	Losartan Potassium	687	189
Amlodipine Besylate	Amlodipine Besylate	628	174
Levothyroxine Sodium	Levothyroxine Sodium	614	165
Metoprolol Succinate	Metoprolol Succinate	584	160
Omeprazole	Omeprazole	530	164
Lisinopril	Lisinopril	468	138
Simvastatin	Simvastatin	408	105
Lorazepam	Lorazepam	388	95
Rosuvastatin Calcium	Rosuvastatin Calcium	380	119
Pantoprazole Sodium	Pantoprazole Sodium	369	107
Gabapentin	Gabapentin	315	76
Albuterol Sulfate Hfa	Albuterol Sulfate	289	100
Hydrochlorothiazide	Hydrochlorothiazide	280	89
Eliquis	Apixaban	271	70
Trazodone Hcl	Trazodone Hcl	261	70
Escitalopram Oxalate	Escitalopram Oxalate	239	67
Tamsulosin Hcl	Tamsulosin Hcl	237	74
Furosemide	Furosemide	223	88
Oxycodone Hcl	Oxycodone Hcl	206	45
Sertraline Hcl	Sertraline Hcl	191	49
Tramadol Hcl	Tramadol Hcl	164	46
Metformin Hcl	Metformin Hcl	161	48
Atenolol	Atenolol	153	41
Citalopram Hbr	Citalopram Hydrobromide	144	37
Fluticasone Propionate	Fluticasone Propionate	142	45
Clonazepam	Clonazepam	141	16
Famotidine	Famotidine	140	44
Prednisone	Prednisone	140	77
Pravastatin Sodium	Pravastatin Sodium	134	42
Allopurinol	Allopurinol	130	38
Xarelto	Rivaroxaban	127	31
Olmesartan Medoxomil	Olmesartan Medoxomil	123	37
Alprazolam	Alprazolam	120	28
Finasteride	Finasteride	120	33
Potassium Chloride	Potassium Chloride	118	39
Zolpidem Tartrate	Zolpidem Tartrate	117	37
Metoprolol Tartrate	Metoprolol Tartrate	115	39
Synthroid	Levothyroxine Sodium	111	30
Duloxetine Hcl	Duloxetine Hcl	109	28
Meloxicam	Meloxicam	93	24
Carvedilol	Carvedilol	92	28
Ezetimibe	Ezetimibe	92	31
Clopidogrel	Clopidogrel Bisulfate	90	33
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	82	25
Montelukast Sodium	Montelukast Sodium	81	18
Valsartan	Valsartan	81	24
Donepezil Hcl	Donepezil Hcl	68	18
Glipizide	Glipizide	68	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	65	25
Methylprednisolone	Methylprednisolone	61	43
Fluoxetine Hcl	Fluoxetine Hcl	58	15
Hydralazine Hcl	Hydralazine Hcl	58	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	58	15
Irbesartan	Irbesartan	58	17
Bupropion Hcl Sr	Bupropion Hcl	57	16
Spironolactone	Spironolactone	56	22
Venlafaxine Hcl Er	Venlafaxine Hcl	55	15
Bupropion Xl	Bupropion Hcl	54	18
Amitriptyline Hcl	Amitriptyline Hcl	53	16
Ibuprofen	Ibuprofen	53	21
Oxycontin	Oxycodone Hcl	50	suppressed
Amoxicillin	Amoxicillin	49	30
Doxycycline Hyclate	Doxycycline Hyclate	48	42
Ondansetron Hcl	Ondansetron Hcl	48	12
Buspirone Hcl	Buspirone Hcl	46	11
Cephalexin	Cephalexin	45	37
Quetiapine Fumarate	Quetiapine Fumarate	44	11
Mirtazapine	Mirtazapine	43	suppressed
Paroxetine Hcl	Paroxetine Hcl	42	11
Pregabalin	Pregabalin	41	16
Klor-Con M20	Potassium Chloride	40	16
Valacyclovir	Valacyclovir Hcl	40	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	39	15
Ropinirole Hcl	Ropinirole Hcl	38	11
Nystatin	Nystatin	37	19
Januvia	Sitagliptin Phosphate	36	11
Warfarin Sodium	Warfarin Sodium	35	suppressed
Clonidine Hcl	Clonidine Hcl	34	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	suppressed
Jardiance	Empagliflozin	33	14
Glimepiride	Glimepiride	32	suppressed
Testosterone	Testosterone	32	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Ventolin Hfa	Albuterol Sulfate	32	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Metformin Hcl Er	Metformin Hcl	31	11
Amiodarone Hcl	Amiodarone Hcl	30	suppressed
Celecoxib	Celecoxib	30	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	30	suppressed
Torsemide	Torsemide	29	suppressed
Glipizide Er	Glipizide	28	suppressed
Trulicity	Dulaglutide	28	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	27	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	26	suppressed
Methenamine Hippurate	Methenamine Hippurate	26	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Azithromycin	Azithromycin	25	21
Digoxin	Digoxin	25	suppressed
Nifedipine Er	Nifedipine	25	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	11
Lovastatin	Lovastatin	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	13
Alfuzosin Hcl Er	Alfuzosin Hcl	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Estradiol	Estradiol	22	11
Ondansetron Odt	Ondansetron	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Temazepam	Temazepam	22	suppressed
Ketoconazole	Ketoconazole	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	21	suppressed
Cefuroxime	Cefuroxime Axetil	20	17
Doxycycline Monohydrate	Doxycycline Monohydrate	20	20
Lamotrigine	Lamotrigine	20	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Metronidazole	Metronidazole	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	18
Labetalol Hcl	Labetalol Hcl	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	12
Clobetasol Propionate	Clobetasol Propionate	18	suppressed
Diazepam	Diazepam	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Nitroglycerin	Nitroglycerin	18	16
Zolmitriptan	Zolmitriptan	18	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Morphine Sulfate	Morphine Sulfate	16	suppressed
Naltrexone Hcl	Naltrexone Hcl	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Latanoprost	Latanoprost	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	14	suppressed
Klor-Con M10	Potassium Chloride	14	suppressed
Loperamide	Loperamide Hcl	14	suppressed
Testosterone Cypionate	Testosterone Cypionate	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Atrovent Hfa	Ipratropium Bromide	13	suppressed
Fenofibrate	Fenofibrate,micronized	13	suppressed
Fentanyl	Fentanyl	13	suppressed
Gemtesa	Vibegron	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Neupro	Rotigotine	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Baclofen	Baclofen	12	suppressed
Balsalazide Disodium	Balsalazide Disodium	12	suppressed
Cilostazol	Cilostazol	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Restasis	Cyclosporine	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	11
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$77.50 · 4 records	Novo Nordisk Inc	AREXVY, BREZTRI, KISUNLA, SHINGRIX, Wegovy	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error